Chest drainage tube capable of slowly releasing analgesic medicine and preparation method of chest drainage tube

Abstract

The invention provides a chest drainage tube for slowly releasing analgesic medicine and a preparation method of the chest drainage tube, and belongs to the technical field of medical nano biological materials. The invention provides a chest drainage tube capable of slowly releasing analgesic medicine. The chest drainage tube comprises a drainage tube body and local anesthetic composite hydrogel loaded on the outer surface of the drainage tube body. The local anesthetic composite hydrogel is attached to the outer surface of the drainage tube and can slowly release the loaded local anesthetic, the hydrogel is used as a drug carrier, the first-time drug loading amount is increased, the effective concentration of the local anesthetic can be maintained in the tube indwelling period through slow degradation of the hydrogel, and the local anesthetic in the tube indwelling period can be reduced. The long-acting analgesic effect is achieved, the basic purpose of postoperative chest drainage can be achieved, the long-term sustainable analgesic effect can be achieved, the adverse effects caused by a traditional analgesic method are obviously reduced, the pain caused by indwelling of a chest duct after a surgery can be obviously relieved, and rehabilitation of the patient is promoted. And theoretical support is provided for subsequent research and expansion to abdominal cavity operations and pelvic cavity operations.

Description

Technical Field

[0001] The invention relates to the technical field of medical nano-biomaterials, and in particular to a chest drainage tube for sustained-release analgesic drugs and a preparation method thereof. Background Art

[0002] Effusion or gas accumulation after thoracic surgery is a common clinical condition. The use of body cavity drainage tubes for such diseases is very extensive. At the same time, improving the comfort of chest drainage tubes is one of the important conditions that affect the accelerated recovery of patients. For example, after thoracic surgery, it is often necessary to place a chest drainage tube to drain pleural effusion, gas accumulation, blood accumulation, and promote lung re-expansion. It also provides a good way to observe whether there is acute blood loss and lung tissue leakage in the chest cavity after surgery. However, during the indwelling of the chest tube, it may compress the intercostal nerves and stimulate the pleura, causing discomfort and possible pain to the patient, affecting the patient's cough and sputum, slowing down lung re-expansion, and being unfavorable for getting out of bed. It also increases the risk of adverse events such as retrograde infection and even pulmonary embolism, thereby prolonging hospitalization and recovery time, increasing medical expenses, and reducing patient satisfaction. At present, most clinical analgesic functions are not achieved, but its duration and subsequent range of action are relatively shallow, which has become a major limitation at present. At present, clinical analgesia for patients after chest drainage tube placement is mostly achieved by puncturing and injecting medium- and long-acting local anesthetics near the puncture site or directly applying lidocaine cream for surface anesthesia. However, the above methods all have obvious disadvantages. For example, when applying lidocaine cream, the onset time is short, and the puncture site is in a humid environment, which is not conducive to healing; secondly, although the local injection of medium- and long-acting local anesthetics can achieve a satisfactory analgesic effect for a certain period of time, the dosage of the drug needs to be strictly controlled to avoid adverse events such as local anesthetics entering the blood and poisoning.

[0003] Therefore, developing a chest drainage tube that can function effectively and sustainably, reduce related pain, and improve the comfort of patients after thoracic surgery has become an important development direction in response to accelerated recovery after surgery. So far, the medical community has no chest drainage tube with the function of sustained release of analgesic drugs. Summary of the invention

[0004] In view of this, the purpose of the present invention is to provide a chest drainage tube for sustained-release analgesics and a preparation method thereof. The chest drainage tube of the present invention can not only meet the basic purpose of postoperative chest drainage, but also achieve long-term sustainable analgesic effect, significantly reducing the adverse effects caused by traditional analgesic methods.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions: The invention provides a chest drainage tube for sustained-release analgesic drugs, comprising a drainage tube and a local anesthetic composite hydrogel loaded on the outer surface of the drainage tube.

[0006] Preferably, the local anesthetic in the local anesthetic composite hydrogel includes one or more of ropivacaine, lidocaine and procaine.

[0007] Preferably, the local anesthetic composite hydrogel is prepared by a method comprising the following steps: mixing a hydrophilic substance and water to obtain a hydrophilic solution; mixing the hydrophilic solution, glycerin and a local anesthetic to obtain a mixture; incubating the mixture to obtain a hydrogel; The hydrogel and the cross-linking agent are mixed to carry out a cross-linking reaction to obtain the local anesthetic composite hydrogel.

[0008] Preferably, the mass percentage of the hydrophilic substance in the mixture is 1-2%, the mass percentage of glycerol is 10-20%, and the mass percentage of the local anesthetic is 0.25-0.75%.

[0009] Preferably, the hydrophilic substance comprises one or more of alginate, gelatin, hyaluronic acid, chitosan and cellulose.

[0010] Preferably, the incubation temperature is 45-60° C. and the time is 5-10 h.

[0011] Preferably, the cross-linking reaction is carried out at a temperature of 25-30° C. and for a time of 3-5 hours.

[0012] Preferably, the drainage tube is made of polyethylene.

[0013] The present invention also provides a method for preparing the chest drainage tube described in the above technical solution, wherein the chest drainage tube is prepared by using a chest drainage tube surface coating device; the chest drainage tube surface coating device comprises: an outer sleeve, one end of the outer sleeve is connected to a sealing plug, an inner sleeve is arranged inside the outer sleeve, and the length of the inner sleeve is greater than that of the outer sleeve; a drainage tube is arranged inside the inner sleeve, the length of the drainage tube is greater than that of the inner sleeve, and the drainage tube passes through the sealing plug, a first liquid injection cavity is formed between the outer sleeve and the inner sleeve, and a second liquid injection cavity is formed between the inner sleeve and the drainage tube; The following steps are involved: A cross-linking agent is injected into the first injection cavity, a hydrogel is injected into the second injection cavity, and the inner sleeve is withdrawn to allow the cross-linking agent and the hydrogel to undergo a cross-linking reaction to obtain the chest drainage tube; the hydrogel contains a local anesthetic.

[0014] Preferably, the extraction speed is 0.5~1 cm / s.

[0015] The invention provides a chest drainage tube for sustained-release analgesic drugs, comprising a drainage tube and a local anesthetic composite hydrogel loaded on the outer surface of the drainage tube.

[0016] Compared with the prior art, the present invention has the following beneficial effects: In the present invention, the local anesthetic composite hydrogel is attached to the outer surface of the drainage tube, and can slowly release the loaded local anesthetic. The hydrogel is used as a drug carrier, which increases the initial drug loading amount, and the slow degradation of the hydrogel allows the local anesthetic to maintain an effective concentration during the catheterization period, thereby achieving a long-lasting analgesic effect. It can not only meet the basic purpose of postoperative chest drainage, but also achieve a long-term sustainable analgesic effect, significantly reduce the adverse effects of traditional analgesic methods, significantly reduce the pain caused by the indwelling chest tube in patients after surgery, promote patient recovery, and provide theoretical support for subsequent research to expand to abdominal surgery and pelvic surgery.

[0017] Furthermore, the hydrogel formed by alginate has excellent tissue compatibility and relative antibacterial properties. The double cross-linked network structure of alginate gives the hydrogel anti-traction and slow dissolution, achieving a longer-lasting analgesic effect.

[0018] Furthermore, the present invention limits the mass percentages of the hydrophilic substance, glycerol and local anesthetic in the mixture, and can obtain a local anesthetic composite hydrogel with suitable and superior morphological characteristics and degradation properties, and has effective and significant long-acting sustained release and analgesic functions.

[0019] The present invention also provides a method for preparing a chest drainage tube for sustained-release analgesic drugs according to the above technical solution. The present invention utilizes a chest drainage tube surface coating device to uniformly fix the local anesthetic composite hydrogel on the surface of the drainage tube in a suitable shape, which is conducive to exerting a uniform local sustained-release effect in the later stage. In addition, the raw materials of the present invention are relatively cheap and easy to obtain. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is a schematic diagram of the structure of a surface coating device for a chest drainage tube; Figure 2 is a schematic diagram of the structure of the sealing plug; Figure 3 The degradation pictures of the chest drainage tube in Example 1 at 0, 3, 12, 36 and 72 hours; Figure 4 TEM image of the cross section of the chest drainage tube in Example 1; Figure 5 This is a TEM image of the longitudinal section of the chest drainage tube of Example 1; Figure 6 The analgesic drug sustained release curve of the local anesthetic composite hydrogel of Examples 1 to 6; Figure 7 It is a bar graph of respiratory rate in different groups; Figure 8 It is a bar graph of tidal volume in different groups; Fig. 9 It is a bar graph of minute ventilation of different groups; Fig.10 The staining results of lung tissue specimens in different groups; In the figure, 1 is an outer sleeve, 2 is an inner sleeve, 3 is a sealing plug, 4 is a drainage tube, 5 is a first injection cavity, 6 is a second injection cavity, 3.1 is an outer ring of the sealing plug, 3.2 is an inner ring of the sealing ring, and 3.3 is an inner hole of the sealing ring; Figures 7-10 A, B, C, D and E represent: A. Data of normal rats without any intervention; B is the blank test group rats with simple chest drainage tube model; C is a control experimental rat implanted with a simple alginate-glycerol hydrogel-coated chest drainage tube model; D is an experimental rat with a hydrogel chest drainage tube model embedded with low-concentration ropivacaine (0.25%); E is an experimental rat with a hydrogel chest drainage tube model embedded with high concentration of ropivacaine (0.75%). DETAILED DESCRIPTION

[0021] The invention provides a chest drainage tube for sustained-release analgesic drugs, comprising a drainage tube and a local anesthetic composite hydrogel loaded on the outer surface of the drainage tube.

[0022] In the present invention, the outer diameter of the drainage tube is preferably 2200 μm.

[0023] In the present invention, the material of the drainage tube is preferably polyethylene (PE), more preferably medical grade polyethylene, and the medical grade polyethylene is preferably made according to the relevant standard YY / T 0114-2008 "Special polyethylene materials for medical infusion, blood transfusion and injection equipment".

[0024] In the present invention, the thickness of the local anesthetic composite hydrogel is preferably 300±20 nm, specifically 280, 290, 300, 310 or 320 nm.

[0025] In the present invention, the local anesthetic in the local anesthetic composite hydrogel preferably includes one or more of ropivacaine, lidocaine and procaine.

[0026] In the present invention, the local anesthetic composite hydrogel is preferably prepared by a method comprising the following steps: mixing a hydrophilic substance and water to obtain a hydrophilic solution; mixing the hydrophilic solution, glycerin and a local anesthetic to obtain a mixture; incubating the mixture to obtain a hydrogel; The hydrogel and the cross-linking agent are mixed to carry out a cross-linking reaction to obtain the local anesthetic composite hydrogel.

[0027] The present invention mixes a hydrophilic substance with water to obtain a hydrophilic solution.

[0028] In the present invention, the hydrophilic substance preferably includes one or more of alginate, gelatin, hyaluronic acid, chitosan and cellulose.

[0029] In the present invention, the alginate is preferably sodium alginate.

[0030] In the present invention, the water is preferably deionized water.

[0031] In the present invention, the concentration of the hydrophilic solution is preferably 0.01-0.02 g / mL, specifically 0.01 or 0.02 g / mL.

[0032] In the present invention, the mixing is preferably stirring, and the stirring temperature is 60° C. The present invention has no particular limitation on the mixing time, as long as a uniform hydrophilic solution can be obtained.

[0033] After obtaining the hydrophilic solution, the present invention mixes the hydrophilic solution, glycerol and a local anesthetic to obtain a mixture.

[0034] In the present invention, the mass percentage of the hydrophilic substance in the mixture is preferably 1-2%, specifically 1% or 2%, the mass percentage of glycerol is preferably 10-20%, specifically 10% or 20%, and the mass percentage of the local anesthetic is preferably 0.25-0.75%, specifically 0.25%, 0.5% or 0.75%.

[0035] In the present invention, the glycerol is preferably added to the hydrophilic solution, stirred until the glycerol and the hydrophilic solution are completely mixed, and then the local anesthetic is added at 45° C. and stirred, and then defoamed to obtain the mixture.

[0036] In the present invention, the defoaming is preferably performed in an ultrasonic cleaning machine.

[0037] After obtaining the mixture, the present invention incubates the mixture to obtain a hydrogel.

[0038] In the present invention, the incubation temperature is preferably 45-60° C., specifically 45, 50, 55 or 60° C., and the incubation time is preferably 5-10 h, specifically 5, 6, 7, 8, 9 or 10 h.

[0039] After obtaining the hydrogel, the present invention mixes the hydrogel and a cross-linking agent to carry out a cross-linking reaction to obtain the local anesthetic composite hydrogel.

[0040] In the present invention, the temperature of the cross-linking reaction is preferably 25-30° C., specifically 25, 26, 27, 28, 29 or 30° C., and the time is preferably 3-5 h, specifically 3, 4 or 5 h.

[0041] In the present invention, the cross-linking agent is preferably a CaCl2 solution, and the mass percentage concentration of the CaCl2 solution is preferably 3%.

[0042] In the present invention, the volume ratio of the hydrogel to the cross-linking agent is preferably 1-2:1, specifically 1:1 or 2:1.

[0043] The present invention also provides a method for preparing the chest drainage tube described in the above technical solution, wherein the chest drainage tube is prepared by using a chest drainage tube surface coating device; the chest drainage tube surface coating device comprises: an outer sleeve, one end of the outer sleeve is connected to a sealing plug, an inner sleeve is arranged inside the outer sleeve, and the length of the inner sleeve is greater than that of the outer sleeve; a drainage tube is arranged inside the inner sleeve, the length of the drainage tube is greater than that of the inner sleeve, and the drainage tube passes through the sealing plug, a first liquid injection cavity is formed between the outer sleeve and the inner sleeve, and a second liquid injection cavity is formed between the inner sleeve and the drainage tube; The following steps are involved: A cross-linking agent is injected into the first injection cavity, a hydrogel is injected into the second injection cavity, and the inner sleeve is withdrawn to allow the cross-linking agent and the hydrogel to undergo a cross-linking reaction to obtain the chest drainage tube; the hydrogel contains a local anesthetic.

[0044] Figure 1 The schematic diagram of the structure of the surface coating device of the chest drainage tube is shown in FIG. 1 is the outer sleeve, 2 is the inner sleeve, 3 is the sealing plug, 4 is the drainage tube, 5 is the first injection cavity, and 6 is the second injection cavity. Figure 1 The surface coating device for a chest drainage tube of the present invention will be described.

[0045] The chest cavity drainage tube surface coating device of the present invention has a double-cavity cylindrical structure and is a movable chest cavity drainage tube surface coating device.

[0046] The surface coating device of the chest drainage tube of the present invention comprises an outer sleeve 1, one end of the outer sleeve 1 is connected to a sealing plug 3, an inner sleeve 2 is arranged inside the outer sleeve 1, and the length of the inner sleeve 2 is greater than that of the outer sleeve 1.

[0047] In the present invention, the outer surface of the outer sleeve 1 is preferably provided with scale lines, and the inner sleeve 2 is preferably arranged in the middle of the outer sleeve 1 .

[0048] In the present invention, the length of the inner sleeve 2 is preferably 1-2 cm longer than that of the outer sleeve 1 .

[0049] In the present invention, a drainage tube 4 is preferably provided in the middle of the inner sleeve 2. The length of the drainage tube 4 is greater than that of the inner sleeve 2. One end of the drainage tube 4 just passes through the sealing plug 3 on the bottom surface of the outer sleeve 1 so that the other end of the drainage tube 4 passes through the upper end of the inner sleeve 2 by 2 to 3 cm.

[0050] Figure 2 It is a schematic diagram of the structure of the sealing plug, wherein 3.1 is the outer ring of the sealing plug, 3.2 is the inner ring of the sealing ring, and 3.3 is the inner hole of the sealing ring. The outer ring 3.1 of the sealing plug is connected to the outer sleeve 1, the inner ring 3.2 of the sealing ring is connected to the inner sleeve 2, and the inner hole 3.3 of the sealing ring is passed through by the drainage tube 4.

[0051] In the present invention, a first liquid injection cavity 5 is formed between the outer sleeve 1 and the inner sleeve 2 , and a second liquid injection cavity 6 is formed between the inner sleeve 2 and the drainage tube 4 .

[0052] In the present invention, the outer sleeve 1 and the inner sleeve 2 are preferably made of polyethylene, more preferably medical grade polyethylene, and the medical grade polyethylene is preferably made according to the relevant standard YY / T 0114-2008 "Special polyethylene materials for medical infusion, blood transfusion and injection equipment".

[0053] In the present invention, the material of the sealing plug 3 is preferably cis-1,4-polybutadiene rubber.

[0054] In the present invention, the surface coating device of the chest drainage tube is preferably first ultrasonically cleaned in deionized water before use.

[0055] In the present invention, the extraction speed is preferably 0.5-1 cm / s, specifically 0.5, 0.6, 0.7, 0.8, 0.9 or 1 cm / s.

[0056] In a specific embodiment of the present invention, the mixture is injected into the second injection cavity 6 for incubation to obtain a hydrogel; the cross-linking agent is added to the first injection cavity 5, preferably until the liquid level is 5 mm from the top of the outer sleeve 1; the upper end of the inner sleeve 2 is held, the lower end of the outer sleeve 2 is looked at, and the inner sleeve 2 is pulled out vertically to the ground until the inner sleeve 2 is completely pulled out of the chest drainage tube surface coating device, at which time the hydrogel in the first injection cavity 6 and the cross-linking agent in the first injection cavity 5 are in contact with each other for a cross-linking reaction; after the cross-linking reaction is completed, the local anesthetic composite hydrogel is obtained. In the present invention, the upper end of the drainage tube 4 is preferably held and pulled out vertically to the ground until the drainage tube is completely pulled out of the chest drainage tube surface coating device, and then the drainage tube 4 is rinsed slowly with deionized water, dried for standby use, and the chest drainage tube is obtained.

[0057] In the present invention, the local anesthetic composite hydrogel is prepared in the same manner as in the above technical solution, which will not be described in detail herein.

[0058] The technical solutions in the present invention will be described clearly and completely below in conjunction with the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0059] Example 1 exist Figure 1 A chest drainage tube is prepared in the chest drainage tube surface coating device shown, and the chest drainage tube surface coating device includes an outer sleeve 1 and an inner sleeve 2, one end of the outer sleeve 1 is connected to a sealing plug 3, the inner sleeve 2 is placed in the middle of the outer sleeve 1, the inner sleeve 2 is 2 cm longer than the outer sleeve 1, a drainage tube 4 is placed in the middle of the inner sleeve 2, one end of the drainage tube 4 just passes through the sealing plug 3 on the bottom surface of the outer sleeve 1 so that the other end of the drainage tube 4 passes through 3 cm from the upper end of the inner sleeve 2, a first liquid injection cavity 5 is formed between the outer sleeve 1 and the inner sleeve 2, and a second liquid injection cavity 6 is formed between the inner sleeve 2 and the drainage tube 4, the outer sleeve 1, the inner sleeve 2 and the drainage tube 4 are made of medical grade polyethylene, and the sealing plug 3 is made of cis-1,4-polybutadiene rubber.

[0060] The preparation method is as follows: S1, the drainage tube 4 and the surface coating device of the chest drainage tube are ultrasonically cleaned in deionized water to remove surface impurities, and assembled for use; S2, dissolving sodium alginate in deionized water, stirring continuously at 60° C. to form a concentrated hydrophilic solution; S3, adding glycerol to the hydrophilic solution in S2, and continuing to stir until the glycerol and the hydrophilic solution are completely mixed; S4, adding local anesthetic ropivacaine at 45°C and stirring to obtain a mixture, wherein the mass fraction of sodium alginate is 2%, the mass fraction of glycerol is 10%, and the mass fraction of ropivacaine is 0.25%; S5, placing the mixture in an ultrasonic cleaning machine for defoaming, and injecting it into the second injection cavity 6 of the chest drainage tube surface coating device. Incubate the chest drainage tube surface coating device at 45° C. for 5 hours until the mixture forms a hydrogel; S6, adding a CaCl2 solution with a mass percentage concentration of 3% as a cross-linking agent into the first injection cavity 5 of the chest drainage tube surface coating device until the liquid level is 5 mm from the top of the outer sleeve 1 of the chest drainage tube surface coating device; S7, holding the upper end of the inner cannula 2, looking at the outer lower end of the inner cannula 2, and pulling it out vertically at a speed of 1 cm per second until the inner cannula 2 is completely pulled out of the chest drainage tube surface coating device. At this time, the hydrogel in the second injection cavity 6 and the cross-linking agent in the first injection cavity 5 are in contact with each other and cross-linked; S8, soaking the surface coating device of the chest drainage tube at 25° C. for 3 hours to allow the hydrogel and the cross-linking agent to be completely cross-linked, thereby obtaining; S9, holding the upper end of the drainage tube 4, pull it out vertically to the ground until the drainage tube 4 is completely pulled out of the chest drainage tube surface coating device.

[0061] S10. Rinse the drainage tube in S9 three times with deionized water at a slow flow rate, dry it in the air and set it aside for use, thereby obtaining a chest drainage tube.

[0062] The degradation performance of the prepared chest drainage tube was tested: the sample was immersed in PBS with a pH value of 7.4 and continuously stirred with a magnetic stirrer at 37°C and a rotation speed of 30 rpm to simulate the body fluid environment in the chest cavity of rats during activities.

[0063] Figure 3 The chest drainage tube is degraded in the following processes at 0, 3, 12, 36 and 72 hours. It can be seen that the surface of the chest drainage tube of the present invention can be degraded.

[0064] Figure 4 This is a TEM image of a cross section of a chest drainage tube. Figure 5 TEM image of the longitudinal section of the chest drainage tube.

[0065] Example 2 The same as Example 1, the only difference is that the mass fraction of sodium alginate in the mixture is 2%, the mass fraction of glycerol is 10%, and the mass fraction of ropivacaine is 0.5%.

[0066] Example 3 The same as Example 1, the only difference is that the mass fraction of sodium alginate in the mixture is 2%, the mass fraction of glycerol is 10%, and the mass fraction of ropivacaine is 0.75%.

[0067] Example 4 The same as Example 1, except that the mass fraction of sodium alginate in the mixture is 2%, the mass fraction of glycerol is 20%, and the mass fraction of ropivacaine is 0.25%.

[0068] Example 5 The same as Example 1, the only difference is that the mass fraction of sodium alginate in the mixture is 2%, the mass fraction of glycerol is 20%, and the mass fraction of ropivacaine is 0.5%.

[0069] Example 6 The same as Example 1, the only difference is that the mass fraction of sodium alginate in the mixture is 2%, the mass fraction of glycerol is 20%, and the mass fraction of ropivacaine is 0.75%.

[0070] The analgesic sustained release effect of the local anesthetic composite hydrogel prepared in Examples 1 to 6 in a simulated in vivo environment was tested. The specific test conditions and methods were as follows: 1 mL of the local anesthetic composite hydrogel was placed in a glass tube, 4 mL of PBS (pH 7.4) was added to each glass tube, and then the glass tube was placed in a 37°C water bath and shaken at 50 rpm for drug release. At predetermined time intervals (10 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h), 1 mL of the release medium (PBS) was taken out for analysis and replaced with the same volume of fresh PBS. The cumulative release amount was calculated as follows: Cumulative drug release rate: , Where E(%) is the cumulative release rate, V E is the extraction volume (1 mL), V0 is the starting volume (4 mL), C i and C n is the concentration of local anesthetic, i and n are the sampling times, and m0 is the total amount of drug loaded in the local anesthetic composite hydrogel.

[0071] The results are as follows Figure 6 As shown in the figure, the drug release of alginate hydrogel is a burst release in the first 24 hours, and reaches a release plateau after 72 hours. At the same time, it can be observed that high initial drug dose and glycerol concentration reduce the cumulative drug release rate. With the increase of drug content and glycerol content, the cross-linking density of the hydrogel will also increase, and the porosity will decrease, which will hinder the release of the drug and eventually lead to a slower release rate.

[0072] In the present invention, the alginate hydrogel containing 0.25% ropivacaine and 10% glycerol exhibits better drug release performance, allowing the local drug concentration to reach a therapeutic level, and this result is also verified in animal experiments.

[0073] Analgesic effect verification When the body is in pain, it often shows rapid protective breathing. Through animal experiments, non-invasive respiratory function tests were performed on experimental mice after the experimental model was established. The results are as follows: Figures 7-9 As shown, Figures 7-9A is the data of normal rats without any intervention, B is the blank test group rats implanted with a simple chest drainage tube model, C is the control experimental rats implanted with a simple alginate-glycerol hydrogel-coated chest drainage tube model, D is the experimental rats implanted with a low-concentration ropivacaine local anesthetic composite hydrogel chest drainage tube model (Example 1, low-concentration ropivacaine, 0.25%), E is the experimental rats implanted with a high-concentration ropivacaine local anesthetic composite hydrogel chest drainage tube model (Example 3, high-concentration ropivacaine, 0.75%), Figure 7 The respiratory rate bar graphs of different groups are shown in Figure 2. Figure 8 The bar graphs of tidal volume for different groups are shown in Figure 2. Fig. 9 The bar graphs are of minute ventilation of different groups. It can be seen that the present invention can effectively reduce stress-induced accelerated breathing in rats after catheterization, that is, the local anesthetic composite hydrogel of the present invention has an ideal and comfortable analgesic effect.

[0074] Anti-inflammatory effect After the analgesic effect was verified, the lung tissue of the rats after the intubation was collected and stained. The results are shown in Fig.10 It can be observed that the inflammatory exudate on the surface of the lung tissue of rats using the present invention is significantly smaller than that of the simple chest drainage tube group and the simple hydrogel-coated chest drainage tube, indicating that the present invention can achieve an anti-inflammatory effect by reducing inflammatory exudate.

[0075] In summary, the local anesthetic composite hydrogel prepared in Example 1 of the present invention is the most suitable and superior composite hydrogel with morphological characteristics and degradation performance. It is fixed on the simulated chest drainage tube and has effective and significant long-acting sustained release and analgesic functions; the chest drainage tube surface coating device of the present invention can make the local anesthetic composite hydrogel evenly fixed on the chest drainage tube in the most suitable shape, which is conducive to the uniform local sustained release effect in the later stage.

[0076] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be regarded as the protection scope of the present invention.

Claims

1. A chest drainage tube for sustained-release analgesics, characterized in that: The invention comprises a drainage tube and a local anesthetic composite hydrogel loaded on the outer surface of the drainage tube.

2. The chest drainage tube according to claim 1, characterized in that: The local anesthetic in the local anesthetic composite hydrogel includes one or more of ropivacaine, lidocaine and procaine.

3. The chest drainage tube according to claim 1 or 2, characterized in that: The local anesthetic composite hydrogel is prepared by a method comprising the following steps: mixing a hydrophilic substance and water to obtain a hydrophilic solution; mixing the hydrophilic solution, glycerol and a local anesthetic to obtain a mixture; incubating the mixture to obtain a hydrogel; The hydrogel and the cross-linking agent are mixed to carry out a cross-linking reaction to obtain the local anesthetic composite hydrogel.

4. The chest drainage tube according to claim 3, characterized in that: The mass percentage of the hydrophilic substance in the mixture is 1-2%, the mass percentage of glycerol is 10-20%, and the mass percentage of the local anesthetic is 0.25-0.75%.

5. The chest drainage tube according to claim 3, characterized in that: The hydrophilic substance includes one or more of alginate, gelatin, hyaluronic acid, chitosan and cellulose.

6. The chest drainage tube according to claim 3, characterized in that: The incubation temperature is 45-60° C. and the incubation time is 5-10 hours.

7. The chest drainage tube according to claim 3, characterized in that: The cross-linking reaction is carried out at a temperature of 25-30° C. and for a time of 3-5 hours.

8. The chest drainage tube according to claim 1, characterized in that: The drainage tube is made of polyethylene.

9. The method for preparing the chest drainage tube according to any one of claims 1 to 8, characterized in that: The chest drainage tube is prepared by using a chest drainage tube surface coating device; the chest drainage tube surface coating device comprises: an outer sleeve, one end of the outer sleeve is connected to a sealing plug, an inner sleeve is arranged inside the outer sleeve, and the length of the inner sleeve is greater than that of the outer sleeve; a drainage tube is arranged inside the inner sleeve, the length of the drainage tube is greater than that of the inner sleeve, and the drainage tube passes through the sealing plug, a first liquid injection cavity is formed between the outer sleeve and the inner sleeve, and a second liquid injection cavity is formed between the inner sleeve and the drainage tube; The following steps are involved: A cross-linking agent is injected into the first injection cavity, a hydrogel is injected into the second injection cavity, and the inner sleeve is withdrawn to allow the cross-linking agent and the hydrogel to undergo a cross-linking reaction to obtain the chest drainage tube; the hydrogel contains a local anesthetic.

10. The preparation method according to claim 9, characterized in that: The extraction speed is 0.5-1 cm / s.

Images